Olatoyosi Odenike to Biomarkers
This is a "connection" page, showing publications Olatoyosi Odenike has written about Biomarkers.
Connection Strength
0.145
-
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep. 2020 12; 15(6):409-418.
Score: 0.122
-
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2017 02; 31(2):393-402.
Score: 0.023